ALT5 Sigma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Peter Tassiopoulos

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	5yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

Mar 31

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03

CEO

Peter Tassiopoulos (55 yo)

less than a year

Tenure

Mr. Peter Tassiopoulos is a Director at ALT5 Sigma Corporation since December 18, 2024 and is its Chief Executive Officer since August 2024. Mr. Tassiopoulos brings over many years of leadership experience...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tony Isaac	President	9.6yrs	US$817.71k	1.73% $ 937.0k
Virland Johnson	Chief Financial Officer	7.3yrs	US$349.35k	0.021% $ 11.5k
Peter Tassiopoulos	CEO & Director	less than a year	no data	no data
Tony Giordano	Chief Scientific Officer	5yrs	no data	no data
Douglas Flanagan	Chief Formulation Advisor	4.5yrs	no data	no data

5.0yrs

Average Tenure

62yo

Average Age

Experienced Management: ALTS's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tony Isaac	President	9.6yrs	US$817.71k	1.73% $ 937.0k
Peter Tassiopoulos	CEO & Director	no data	no data	no data
Richard Butler	Independent Director	9.6yrs	US$30.00k	0.10% $ 53.8k
John Cooke	Member of Scientific Advisory Board	4.4yrs	no data	no data
Nicholas Goeders	Member of Scientific Advisory Board	3.5yrs	no data	no data
Christopher Kevil	Chair of Scientific Advisory Board	4.9yrs	no data	no data
Edgar Ross	Member of Scientific Advisory Board	4.4yrs	no data	no data
Nael Hajjar	Independent Director	6.3yrs	US$14.40k	no data
John Bitar	Independent Director	4.9yrs	US$18.00k	0.014% $ 7.7k
Ron Pitters	Independent Director	less than a year	no data	no data
Joshua Beckman	Member of Scientific Advisory Board	no data	no data	no data

4.7yrs

Average Tenure

59yo

Average Age

Experienced Board: ALTS's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 05:13
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/28
Annual Earnings	2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALT5 Sigma Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ryan McGaver	Capstone Investments

ALT5 Sigma Management

Management criteria checks 2/4

Key information

Recent management updates

ALT5 Sigma Corporation Elects Peter Tassiopoulos to the Board

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

Insufficient new directors

Recent updates

ALT5 Sigma Corporation Elects Peter Tassiopoulos to the Board

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

High number of new directors

ALT5 Sigma Corporation Appoints Ron Pitters to Its Board of Directors

ALT5 Sigma Corporation, Annual General Meeting, Dec 18, 2024

ALT5 Sigma Corporation Announces Chief Executive Officer Changes

ALT5 Sigma Corporation announced delayed 10-Q filing

Insufficient new directors

JanOne Regains Compliance with Nasdaq's Listing Rule 5550(b)(1)

JanOne Inc. (NasdaqCM:JAN) completed the acquisition of Alt 5 Sigma Inc.

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

JanOne Inc. announced delayed annual 10-K filing

JanOne Regains Compliance with Nasdaq’s Listing Requirements

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 93%

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

New minor risk - Profit margin trend

New major risk - Shareholder dilution

New major risk - Share price stability

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne Receives Non-Compliance Notice from the Nasdaq Stock Market

JanOne Inc., Annual General Meeting, Oct 09, 2023

New minor risk - Share price stability

New major risk - Earnings quality

Janone Inc. Files International Patent Application for Methods of Using Low Dose Naltrexone to Treat Chronic Pain

JanOne Inc. announced delayed 10-Q filing

Full year 2022 earnings released: EPS: US$1.14 (vs US$6.35 loss in FY 2021)

JanOne Received A Notice from the NASDAQ Stock Market

Third quarter 2022 earnings released: US$0.66 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

JanOne Inc., Annual General Meeting, Nov 02, 2022

JanOne Inc. (NasdaqCM:JAN) enter into a term sheet to acquire Soin Therapeutics LLC Soin Therapeutics LLC for $30 million.

JanOne to acquire Soin Therapeutics

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: US$3.39 (vs US$2.07 loss in 2Q 2021)

JanOne Inc. Announces an Improved Formulation of JAN101

JanOne Inc. Announces the Issuance of U.S. Patent Covering A Method of Improving Nerve Function Using Jan101

First quarter 2022 earnings released: EPS: US$0.43 (vs US$0.26 in 1Q 2021)

High number of new and inexperienced directors

JanOne Receives Notice from Nasdaq for Not Complying with Listing Rules

Full year 2021 earnings released: US$6.35 loss per share (vs US$4.59 loss in FY 2020)

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new and inexperienced directors

Janone Janone Inc. Revises Its Development Strategy Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate Jan101

Janone Inc. Readies Clinical Supply of Lead Product Candidate Jan101 for Distribution to Phase 2B Trial Sites

JanOne Selects Regulatory Partner for Phase 2B Trial as Investigational Plan Is Prepared for FDA Filing

JanOne adds Nicholas Goeders to scientific advisory board

JanOne Announces Initiation of Phase 2b Peripheral Artery Disease Trial for Lead Product Candidate JAN101

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Chief Financial Officer recently sold US$221k worth of stock

First quarter 2021 earnings released: EPS US$0.26 (vs US$1.33 loss in 1Q 2020)

Full year 2020 earnings released: US$4.59 loss per share (vs US$6.78 loss in FY 2019)

Virland Johnson entered into a definitive agreement to acquire substantially all assets and certain liabilities of ARCA Recycling, Inc. from JanOne Inc. (NasdaqCM:JAN) for $25 million.

JanOne Inc. has completed a Follow-on Equity Offering in the amount of $5.999994 million.

JanOne under pressure on pricing $6M stock offering

New 90-day high: US$5.47

New 90-day high: US$5.08

Third quarter 2020 earnings released: US$0.43 loss per share

New 90-day low: US$3.50

JanOne Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study

New 90-day high - US$5.86

Earnings released

New 90-day high - US$3.74

CEO

Tenure

Leadership Team